

The Benchmark Company, LLC
150 E 58th Street, 17th floor
New York, NY 10155

Dawson James Securities, Inc.
1 North Federal Highway, 5th Floor
Boca Raton, FL 33432

December 19, 2017

VIA EDGAR

Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549

Re: Acasti Pharma, Inc. (the "Company")
Registration Statement on Form F-1
File No. 333-220755

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended (the "Securities Act"), the undersigned, as underwriter of the proposed offering, hereby joins the request of Acasti Pharma, Inc. that the effective date of the above-referenced Registration Statement on Form F-1 be declared effective at 4:30 p.m. (Washington, D.C. time) on Tuesday, December 19, 2017, or as soon as practicable thereafter.

In connection with this acceleration request and pursuant to Rule 460 under the Securities Act, please be advised that between December 15, 2017 and the date hereof, approximately 1,350 copies of the preliminary prospectus dated December 14, 2017 were distributed to underwriters, dealers, institutions and others.

The undersigned advise that the underwriters have complied and will continue to comply with Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.

Sincerely,

The Benchmark Company, LLC

By: /s/ John J. Borer

Name: John J. Borer

Title: Senior Managing Director

Dawson James Securities, Inc.

By: /s/ Robert D. Keyser, Jr.

Name: Robert D. Keyser, Jr.

Title: CEO